Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.10USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$1.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
718,954
52-wk High
$5.15
52-wk Low
$1.01

ALIM.O

Chart for ALIM.O

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 3.17
Market Cap(Mil.): $75.89
Shares Outstanding(Mil.): 64.86
Dividend: --
Yield (%): --

Financials

  ALIM.O Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -0.80 -- --
ROI: -54.46 15.56 14.95
ROE: -- 16.69 16.29

BRIEF-Stonepine Capital LP reports 5.4 pct passive stake in Alimera Sciences

* Stonepine Capital LP reports 5.4 percent passive stake in Alimera Sciences Inc as of Nov 7 - sec filing Source text : http://bit.ly/2eKIZdy Further company coverage:

Nov 17 2016

BRIEF-Alimera Sciences reports Q3 loss per share $0.16

* Q3 earnings per share view $-0.11, revenue view $10.5 million -- Thomson Reuters I/B/E/S

Nov 02 2016

BRIEF-Alimera Sciences begins selling iluvien in the Middle East

* Alimera Sciences begins selling iluvien in the middle east

Oct 26 2016

BRIEF-Alimera Sciences strengthens financial position

* Under amendment, hercules has agreed to provide limited up to $10 million in additional financing upon achievement of certain revenue milestones

Oct 20 2016

BRIEF-Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing

* Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing Source text for Eikon: Further company coverage:

Aug 22 2016

BRIEF-Alimera Sciences prices public offering of common stock

* Says public offering of 18.0 million common shares priced at $1.40per share Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Alimera Sciences proposes public offering of common stock

* All shares in offering are to be sold by Alimera, with net proceeds to be used to fund continued commercialization of Iluvien Source text for Eikon: Further company coverage:

Aug 10 2016

BRIEF-Alimera Sciences Q2 GAAP loss per share $0.15

* Alimera sciences announces second quarter 2016 financial results and provides business update

Aug 03 2016

BRIEF-Alimera Sciences sees Q2 revenue of $9.3 mln - $9.5 mln

* Says modified liquidity and revenue covenants in its existing loan agreement with Hercules Capital Inc

Jul 26 2016

Earnings vs. Estimates